The global biopharmaceutical industry is evolving rapidly, driven by advances in biologics, cell and gene therapies, and an increasing demand for scientific insight alongside analytical support. 

For a world leader in testing, inspection, and certification, SGS sees this evolution as an opportunity to strengthen its role as a trusted partner to both established pharmaceutical companies and emerging biotechs.

In this Q&A, I spoke with Liên-Anh Tran, Group Vice President for Pharma, Cosmetics & Personal Care, who discussed the company’s global strategy, innovation focus, and the growing importance of scientific collaboration across its expanding network.

How would you describe SGS’s current position and focus in the market?

We’re in a strong position globally, recognised for our broad network, our scientific depth and our ability to support complex development programs. Our focus is clear: expanding our footprint in Europe, North America, and Asia, and strengthening our capabilities in large-molecule analytics and bioanalysis. Our Irish laboratory is an important part of that global network.

What trends are shaping the coming years in biopharma?

The shift toward biologics and advanced therapies continues to accelerate, creating a growing need for advanced characterization and bioanalytical support. However, tighter venture capital funding is slowing early-stage biotech activity, which is reshaping how clients prioritise and outsource their programs.

Where do you see the biggest growth opportunities for SGS?

Growth will come from expanding our large-molecule services and deepening bioanalytical support across clinical programs. There’s also a strong opportunity to work more closely with emerging biotechs who need both scientific guidance and analytical execution.

How is SGS adapting to changing client expectations?

Clients today want quick, clear answers from partners who understand their science. We’ve become more consultative and agile, enhancing our technical capabilities to support new and emerging modalities. Staying close to clients allows us to anticipate needs and deliver the right solutions faster.

What role does innovation play in SGS’s operations?

Innovation is at the core of what we do. It’s not only about new technologies but also about our people — continuously developing expertise to meet new therapeutic challenges. At SGS, innovation means anticipating change and equipping our teams to solve the problems of tomorrow.

How important are partnerships and collaborations?

They’re absolutely central. Whether with established pharma companies or emerging biotechs, collaboration keeps us ahead of scientific trends and ensures we’re contributing to clients’ development strategies. In Ireland, these partnerships are particularly valuable to advancing the life sciences ecosystem.

What differentiates SGS from competitors?

We combine scientific depth with a collaborative, client-focused approach. We’re large enough to support global programmes, yet agile enough to deliver tailored, local service. That balance gives clients confidence and flexibility across all stages of development.

How does SGS contribute to wider progress?

By helping bring new therapies to market faster and safely, we directly support better patient outcomes. Locally, we invest in high-value scientific jobs, training, and engagement with Ireland’s life sciences community, contributing to both economic growth and innovation.

What challenges lie ahead for the sector?

The current slowdown in early-stage biopharma, driven by reduced VC funding, is the main challenge. At the same time, molecules are becoming more complex and timelines shorter. We’re responding by strengthening our scientific teams and adapting our technology to stay ahead of analytical demands.

Where do you see SGS in five years?

We aim to be a global leader in small- and large-molecule testing and advanced bioanalysis, with a wider footprint across Europe, North America, and Asia. Our Irish operations will continue to grow in importance as we expand our role as a trusted scientific partner known for excellence, collaboration, and innovation.

At Pharma Industry Awards

SGS found the opportunity not only to showcase its leadership in advanced bioanalysis but also to connect with a dynamic community of biopharma innovators, researchers, and development partners. 

The event provided valuable networking opportunities and fresh insights into how the sector is adapting to new scientific and economic realities.

Celebrate your organisation’s achievements in the life sciences. Stay tuned for the upcoming Pharma Industry Awards 2025, where leaders, innovators, and collaborators come together to recognise excellence and shape the future of the industry.